The 14 most recent market catalysts affecting $CADL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 55
Multiple Financial Institutions Update Ratings and Price Targets for Candel Therapeutics
On November 14, 2026, several prominent financial institutions, including Bank of America and Stifel, updated their research on Candel Therapeutics. While all firms maintained thei…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 75
Block & Leviton Investigates Candel Therapeutics for Potential Securities Law Violations
Block & Leviton has launched an investigation into Candel Therapeutics (CADL) regarding potential securities law violations. The core issue is whether the company provided accurate…
Nov 13, 2026
Corporate Catalyst
Neutral
Impact 85
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Updates BLA Submission Timeline
Candel Therapeutics disclosed a Q3 2026 operating loss of $23 million, a substantial increase from $13.2 million in Q3 2025. More significantly, the company announced a delay in it…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Adjusts Price Target on Candel Therapeutics
Stifel, an investment bank, has adjusted its price target for Candel Therapeutics (CADL) from $22 to $19. This change comes after the company's third-quarter financial reporting an…
Nov 7, 2026
Corporate Catalyst
Neutral
Impact 55
Candel Therapeutics Presents Clinical and Biomarker Data at SITC 41st Annual Meeting
Candel Therapeutics (CADL) announced the presentation of clinical and biomarker data from three posters at the SITC 41st Annual Meeting. This event is a routine update for a biotec…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 75
Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.
Candel Therapeutics has published the final results of its Phase 2a clinical trial for aglatimagene besadenovec (agla) in combination with valacyclovir for patients with Stage III/…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer
Candel Therapeutics (CADL) has released encouraging immunological biomarker data from its ongoing Phase 2 PrTK05 trial for prostate cancer. The data demonstrates T-cell activation,…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Candel Therapeutics shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $12 to $18.
This headline represents a significant corporate catalyst for Candel Therapeutics. Analyst upgrades from major institutions like BofA Securities often lead to increased investor co…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18
B of A Securities analyst Alec Stranahan upgraded Candel Therapeutics (CADL) from Neutral to Buy and raised the price target from $12 to $18. This upgrade reflects a more optimisti…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
The filing indicates that HC Wainwright & Co. analyst Andres Y. Maldonado has reaffirmed a 'Buy' rating and a $23 price target for Candel Therapeutics. This action signals continue…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate
Candel Therapeutics (CADL) reported a Q2 EPS of $(0.52), missing analyst estimates of $(0.23) by a substantial 126.09%. This significant earnings miss, coupled with a 477.78% incre…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22
Stifel analyst Stephen Willey has initiated coverage on Candel Therapeutics (CADL) with a 'Buy' rating and a $22 price target. This event is significant for CADL as it introduces n…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.